4-chloro-6-cyclopentylpyrimidine | 768397-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-chloro-6-cyclopentylpyrimidine
• CAS: 768397-44-0
• 化学式: C₉H₁₁ClN₂
• 分子量: 182.653
• InChiKey: RUKCYYSKRPBXHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-6-cyclopentylpyrimidine 、 N-(4-(4-methylpiperazin-1-yl)methyl)phenyl-4-amino-1H-pyrazole-3-carboxamide 在 溶剂黄146 作用下， 以 水 为溶剂， 以71%的产率得到4-((6-cyclopentylpyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  4-(芳杂环取代)氨基-1H-3-吡唑甲酰胺类 FLT3抑制剂及其用途

  摘要：

  本发明涉及一种新型4‑(芳杂环取代)氨基‑1H‑3‑吡唑甲酰胺类化合物或其药学可接受的盐、溶剂化物、异构体、酯、酸、代谢物或前药，他们的制备方法，包括含此类化合物的药用组合物、以及它们的医疗用途。

  公开号：

  CN107245073B
• 作为产物：
  描述：

  6-Cyclopentylpyrimidin-4-ol 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以0.72 g的产率得到4-chloro-6-cyclopentylpyrimidine
  参考文献：
  名称：

  Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor

  摘要：

  we describe the discovery of compound LT-540-717 (32), a potent FLT3 inhibitor (IC50: 0.62 nM), starting from FN-1501. Compound 32 exhibited highly inhibitory activity against several acquired FLT3 mutations including FLT3 (ITD, D835V), FLT3 (ITD, F691L), FLT3 (D835Y) and FLT3 (D835V). Additionally, 32 displayed potent antiproliferative activity against FLT3-mutation driven BaF3 and AML cells. Oral administration

  DOI：

  10.1016/j.ejmech.2023.115448

文献信息

• 4-(芳杂环取代)氨基-1H-3-吡唑甲酰胺类 FLT3抑制剂及其用途
  申请人：中国药科大学

  公开号：CN107245073B

  公开（公告）日：2020-04-17

  本发明涉及一种新型4‑(芳杂环取代)氨基‑1H‑3‑吡唑甲酰胺类化合物或其药学可接受的盐、溶剂化物、异构体、酯、酸、代谢物或前药，他们的制备方法，包括含此类化合物的药用组合物、以及它们的医疗用途。
• Substituted pyrimidines as cannabinoid CB1 receptor ligands
  作者：Min Ju Kim、Jong Yup Kim、Hee Jeong Seo、Junwon Lee、Sung-Han Lee、Mi-Soon Kim、Jahyo Kang、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmcl.2009.06.069

  日期：2009.8

  Cannabinoid CB1 receptors have been the avenue of extensive studies since the first clinical results of rimonabant (SR141716)for the treatment of obesity and obesity-related metabolic disorders were reported in 2001. To further evaluate the properties of CB receptors, we have designed and efficiently prepared a series of substituted pyrimidines based on chemical structure of Merck's taranabant, a cannabinoid CB1 receptor inverse agonist. Noticeably, N4-((2S,3S)-3-(3-bromophenyl)-4-(4-chlorophenyl)butan-2-yl)-N6-butylpyrimidine-4,6-diamine (13b) demonstrated good binding affinity and decent selectivity for CB1 receptor (IC50 = 16.3 nM, CB2/CB1 = 181.6). (C) 2009 Elsevier Ltd. All rights reserved.
• Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor
  作者：Yanle Zhi、Hongmei Li、Pei Yang、Qiaomei Jin、Chao Yao、Baoquan Li、Jun Ling、Hao Guo、Tonghui Li、Jianlin Jin、Yue Wang、Yadong Chen、Tao Lu、Shuai Lu

  DOI：10.1016/j.ejmech.2023.115448

  日期：2023.8

  we describe the discovery of compound LT-540-717 (32), a potent FLT3 inhibitor (IC50: 0.62 nM), starting from FN-1501. Compound 32 exhibited highly inhibitory activity against several acquired FLT3 mutations including FLT3 (ITD, D835V), FLT3 (ITD, F691L), FLT3 (D835Y) and FLT3 (D835V). Additionally, 32 displayed potent antiproliferative activity against FLT3-mutation driven BaF3 and AML cells. Oral administration